menu ☰
menu ˟

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

Creator:

Lawrie, T.A., et al

Subject Keywords: To assess the efficacy and safety of PLD in women with relapsed epithelial ovarian cancer (EOC)
Set: Cancer
Chronic Conditions
Conditions
Type: Article
Region: International (other)
Description:

The choice of chemotherapy in women with relapsed epithelial ovarian cancer (EOC) is influenced by the duration of the platinum-free interval, the length of time from the last platinum-based cycle to the time of disease progression. Women who relapse within one month of receiving platinum therapy or who progress on therapy are considered to be platinum-refractory; women who relapse between one and six months after platinum therapy are considered to be platinum-resistant; and women who relapse more than six months after platinum therapy are considered to be platinum-sensitive. The latter group is further subgrouped by women who relapse between six and 12 months after platinum therapy (partially platinum-sensitive) and those who relapse after 12 months.

Doxirubicin hydrochloride is an anti-cancer drug that works by interfering with cancer cell DNA. A newer form of doxorubicin called pegylated liposomal doxorubicin (PLD) has been developed with a coating that allows it to reach higher concentrations in cancer cells and with less adverse effects on the heart.

Date:

09/07/2013

Rights: © The Cochrane Collaboration
Suggested citation:

Lawrie, T.A., et al. (2013) Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer [Online]. Available from: http://www.thehealthwell.info/node/525336 [Accessed: 21st May 2018].

  

View your saved citations and reading lists

Contributor:

Other partner websites
 
Click here to view all the resources gathered from this organisation's website.

IPH Logo